ARQT News and Press, Arcutis Biotherapeutics Inc. From 04/05/23

2023-04-05 11:05:28 ET Arcutis Biotherapeutics ( NASDAQ: ARQT ) said its plaque psoriasis cream Zoryve is being covered without prior authorizations by an additional eight national and regional health plans, effective April 1. The company noted that, combined with the pre...

Eight additional national and regional health plans are now covering ZORYVE for plaque psoriasis ZORYVE is a once-daily, steroid-free cream approved for use in both adults and adolescents with plaque psoriasis, including all affected areas of the body WESTLAKE VILLAGE, Calif., April...

New INTEGUMENT-1 and INTEGUMENT-2 data show a rapid and significant reduction in itch as early as 24 hours after the first application of roflumilast cream 0.15% Rapid and significant improvements were achieved including individuals reaching a 75% reduction of Eczema Area and Severity Index (...

2023-03-11 10:00:00 ET Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports a...

2023-03-10 15:00:56 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calenda...

Late breaking session to highlight new data from the INTEGUMENT Phase 3 trials evaluating roflumilast cream in atopic dermatitis New national survey insights depicting disease burden, path to diagnosis and treatment patterns for seborrheic dermatitis New clinical safety and efficacy data ...

Arcutis Biotherapeutics, Inc. (ARQT) Q4 2022 Earnings Conference Call February 28, 2023 04:30 PM ET Company Participants Eric McIntyre - Head of Investor Relations Frank Watanabe - President & Chief Executive Officer Patrick Burnett - Chief Medical Officer Ken ...

Arcutis Biotherapeutics press release ( NASDAQ: ARQT ): Q4 GAAP EPS of -$1.18 beats by $0.27 . Revenue of $2.96M beats by $0.91M . For further details see: Arcutis Biotherapeutics Q4 results beat estimates

The following slide deck was published by Arcutis Biotherapeutics, Inc. in conjunction with their 2022 Q4 earnings call. For further details see: Arcutis Biotherapeutics, Inc. 2022 Q4 - Results - Earnings Call Presentation

Achieved net revenues of $3.0 million for ZORYVE® (roflumilast) cream 0.3% in the first full quarter since the August 2022 launch, driven by continued unit demand growth Secured expanded commercial payer coverage for ZORYVE in plaque psoriasis with the second of the top three pharmacy be...